gemfibrozil and Insulin Sensitivity studies

Research Excerpts

Excerpt	Relevance	Reference
"To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus."	9.10	Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002)
"In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance."	9.09	Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. ( Alessandrini, P; Bittolo Bon, G; Bonfardeci, G; Cimminiello, C; Colombo, L; Mannucci, L; Mussoni, L; Nenci, G; Notarbartolo, A; Parise, P; Pazzucconi, F; Piliego, T; Scafidi, V; Sirtori, C; Tremoli, E, 2000)
"This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity."	9.09	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001)
"We studied the effects of gemfibrozil on glucose and fatty acid metabolism in subjects with mild endogenous hypertriglyceridemia."	9.08	Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. ( Knudsen, P; Sane, T; Taskinen, MR; Vuorinen-Markkola, H; Yki-Järvinen, H, 1995)
"Gemfibrozil or placebo was administered for 3 months to 24 individuals with endogenous hypertriglyceridemia and normal glucose tolerance."	9.08	Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. ( Chen, YD; Fuh, MM; Jeng, CY; Reaven, GM; Sheu, WH; Shieh, SM, 1996)
"The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels > 250 mg/dl and total cholesterol levels < 220 mg/dl."	7.69	Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Lee, MM; Sheu, WH; Shieh, SM, 1997)
"To assess the effect of insulin resistance and the benefit of the fibrate, gemfibrozil, on the incidence of major cardiovascular events in subjects with low HDL cholesterol and a broad range of triglyceride values who participated in the Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT)."	5.10	Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Robins, SJ; Rubins, HB; Schaefer, EJ, 2003)
"To examine whether lowering of plasma triglyceride concentrations using the fibrate peroxisome proliferator-activated receptor (PPAR)alpha agonist gemfibrozil would influence insulin sensitivity to various aspects of intermediary metabolism among subjects with type 2 diabetes mellitus."	5.10	Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. ( Nattrass, M; Smith, JM; Whitelaw, DC, 2002)
"In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance."	5.09	Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. ( Alessandrini, P; Bittolo Bon, G; Bonfardeci, G; Cimminiello, C; Colombo, L; Mannucci, L; Mussoni, L; Nenci, G; Notarbartolo, A; Parise, P; Pazzucconi, F; Piliego, T; Scafidi, V; Sirtori, C; Tremoli, E, 2000)
"This study was designed to determine the effect of a 3 month treatment with Gemfibrozil (GF) on flow-mediated vasodilatation and insulin sensitivity."	5.09	Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. ( Avogaro, A; de Kreutzenberg, S; Del Prato, S; Favaro, A; Gottardo, L; Manzato, E; Miola, M; Pacini, G; Piliego, T; Sacerdoti, D; Tiengo, A; Zambon, S, 2001)
"We studied the effects of gemfibrozil on glucose and fatty acid metabolism in subjects with mild endogenous hypertriglyceridemia."	5.08	Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. ( Knudsen, P; Sane, T; Taskinen, MR; Vuorinen-Markkola, H; Yki-Järvinen, H, 1995)
"Gemfibrozil or placebo was administered for 3 months to 24 individuals with endogenous hypertriglyceridemia and normal glucose tolerance."	5.08	Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. ( Chen, YD; Fuh, MM; Jeng, CY; Reaven, GM; Sheu, WH; Shieh, SM, 1996)
" The radioactive triglyceride triolein readily crossed the BBB and centrally administered triolein and peripherally administered lipids induced in vivo leptin and/or insulin resistance at hypothalamic receptors."	3.88	Triglycerides cross the blood-brain barrier and induce central leptin and insulin receptor resistance. ( Banks, WA; Craft, S; Farr, SA; Hansen, KM; Hanson, AJ; Morley, JE; Niehoff, ML; Rhea, EM; Salameh, TS, 2018)
"Gemfibrozil is a PPAR-α ligand that inhibits the progression of atherosclerosis in insulin resistance type 2 diabetes mellitus (IR type 2 DM)."	3.79	Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats. ( Kurmi, MK; Raikwar, SK; Sharma, AK; Srinivasan, BP, 2013)
"The fibrinolytic and metabolic changes associated with gemfibrozil treatment of hypertriglyceridemia were evaluated in 16 patients with type IV hyperlipidemia by criteria of triglyceride levels > 250 mg/dl and total cholesterol levels < 220 mg/dl."	3.69	Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Lee, MM; Sheu, WH; Shieh, SM, 1997)
"3."	2.68	Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. ( Avogaro, A; Beltramello, P; Biffanti, S; Bonanome, A; Confortin, L; Crepaldi, G; Manzato, E; Marin, R; Tiengo, A; Zambon, S, 1995)
"Hypertriglyceridemia is commonly embedded in the context of a metabolic syndrome that includes central obesity, insulin resistance, low levels of HDL cholesterol, and often hypertension."	2.41	A risk factor for atherosclerosis: triglyceride-rich lipoproteins. ( Kane, JP; Malloy, MJ, 2001)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (31.82)	18.2507
2000's	11 (50.00)	29.6817
2010's	3 (13.64)	24.3611
2020's	1 (4.55)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Exploring the Health Benefits Associated With Daily Pulse Consumption in Individuals With Peripheral Arterial Disease[NCT00755677]			Early Phase 1	26 participants (Actual)	Interventional	2007-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
[Alcoholic and non-alcoholic steatohepatitis]. Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:8 Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver,	2004
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. The American journal of cardiology, 1998, Feb-26, Volume: 81, Issue:4A Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-C	1998
A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Advances in internal medicine, 2001, Volume: 47 Topics: Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxym	2001

Article	Year
Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes care, 2003, Volume: 26, Issue:5 Topics: Body Constitution; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Ty	2003
Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. The American journal of cardiology, 2005, Jan-15, Volume: 95, Issue:2 Topics: Apolipoproteins; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combi	2005
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis, 2006, Volume: 187, Issue:1 Topics: Alleles; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Gemfi	2006
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2007, Volume: 49, Issue:6 Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Elasticity; Endothelium, Vascular;	2007
Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation, 1995, Oct-01, Volume: 92, Issue:7 Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Gemf	1995
Decreasing triglyceride by gemfibrozil therapy does not affect the glucoregulatory or antilipolytic effect of insulin in nondiabetic subjects with mild hypertriglyceridemia. Metabolism: clinical and experimental, 1995, Volume: 44, Issue:5 Topics: Analysis of Variance; Apolipoprotein A-II; Blood Glucose; Cholesterol; Circadian Rhythm; Double-Blin	1995
Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients. Atherosclerosis, 1995, Volume: 113, Issue:1 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Insulin	1995
Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Diabetologia, 1993, Volume: 36, Issue:2 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Interactions; Fatty	1993
Gemfibrozil treatment of endogenous hypertriglyceridemia: effect on insulin-mediated glucose disposal and plasma insulin concentrations. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:7 Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Circadian Rhythm;	1996
Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients. Atherosclerosis, 2000, Volume: 148, Issue:2 Topics: Adult; Aged; Blood Glucose; Double-Blind Method; Fatty Acids, Nonesterified; Gemfibrozil; Glucose To	2000
Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients. European journal of clinical investigation, 2001, Volume: 31, Issue:7 Topics: Aged; Arteriosclerosis; Blood Circulation; Diabetes Mellitus, Type 2; Endothelium, Vascular; Gemfibr	2001
Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes, obesity & metabolism, 2002, Volume: 4, Issue:3 Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind	2002

Article	Year
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway. Archives of pharmacal research, 2023, Volume: 46, Issue:5 Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki	2023
Triglycerides cross the blood-brain barrier and induce central leptin and insulin receptor resistance. International journal of obesity (2005), 2018, Volume: 42, Issue:3 Topics: Aged; Animals; Antigens, CD; Blood-Brain Barrier; Cognition; Female; Gemfibrozil; Humans; Insulin Re	2018
Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease. Journal of lipid research, 2010, Volume: 51, Issue:12 Topics: Aged; Alleles; Case-Control Studies; Cholesterol, HDL; Coronary Disease; Gemfibrozil; Genetic Predis	2010
Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats. Inflammopharmacology, 2013, Volume: 21, Issue:2 Topics: Adiponectin; Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug	2013
Eruptive xanthomas. Dermatology online journal, 2001, Volume: 7, Issue:2 Topics: Adult; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Xanthom	2001
Dysregulation of growth hormone in acquired generalized lipodystrophy. Saudi medical journal, 2004, Volume: 25, Issue:11 Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administrati	2004
Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance. American heart journal, 1997, Volume: 134, Issue:3 Topics: Adult; Aged; Cholesterol, HDL; Female; Fibrinolysis; Gemfibrozil; Humans; Hypertriglyceridemia; Hypo	1997

gemfibrozil and Insulin Sensitivity

Research Excerpts

Research

Studies (22)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Thongnak, L	1
Pengrattanachot, N	1
Promsan, S	1
Phengpol, N	1
Sutthasupha, P	1
Jaikumkao, K	1
Lungkaphin, A	1
Banks, WA	1
Farr, SA	1
Salameh, TS	1
Niehoff, ML	1
Rhea, EM	1
Morley, JE	1
Hanson, AJ	1
Hansen, KM	1
Craft, S	1
Peloso, GM	1
Demissie, S	1
Collins, D	3
Mirel, DB	1
Gabriel, SB	1
Cupples, LA	1
Robins, SJ	3
Schaefer, EJ	3
Brousseau, ME	2
Sharma, AK	1
Raikwar, SK	1
Kurmi, MK	1
Srinivasan, BP	1
Naik, NS	1
Rubins, HB	1
Faas, FH	1
Elam, MB	1
Anderson, JW	1
Dufour, JF	1
Oneta, CM	1
Sahhar, NN	1
Ahmad, AT	1
Ammari, FL	1
Ajlouni, KM	1
Lamendola, C	1
Abbasi, F	1
Chu, JW	1
Hutchinson, H	1
Cain, V	1
Leary, E	1
McLaughlin, T	1
Stein, E	1
Reaven, G	1
Tai, ES	1
O'Connor, JJ	1
Bloomfield, HE	1
Ordovas, JM	1
Dogra, G	1
Irish, A	1
Chan, D	1
Watts, G	1
Tenkanen, L	1
Mänttäri, M	1
Manninen, V	1
Sane, T	1
Knudsen, P	1
Vuorinen-Markkola, H	2
Yki-Järvinen, H	2
Taskinen, MR	2
Avogaro, A	2
Beltramello, P	1
Marin, R	1
Zambon, S	2
Bonanome, A	1
Biffanti, S	1
Confortin, L	1
Manzato, E	2
Crepaldi, G	1
Tiengo, A	2
Jeng, CY	2
Sheu, WH	2
Fuh, MM	1
Shieh, SM	2
Chen, YD	1
Reaven, GM	1
Jeng, JR	1
Lee, MM	1
Huang, SH	1
Vega, GL	1
Grundy, SM	1
Mussoni, L	1
Mannucci, L	1
Sirtori, C	1
Pazzucconi, F	1
Bonfardeci, G	1
Cimminiello, C	1
Notarbartolo, A	1
Scafidi, V	1
Bittolo Bon, G	1
Alessandrini, P	1
Nenci, G	1
Parise, P	1
Colombo, L	1
Piliego, T	2
Tremoli, E	1
Miola, M	1
Favaro, A	1
Gottardo, L	1
Pacini, G	1
Sacerdoti, D	1
de Kreutzenberg, S	1
Del Prato, S	1
Malloy, MJ	1
Kane, JP	1
Whitelaw, DC	1
Smith, JM	1
Nattrass, M	1